Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma

HIGHLIGHTS

• who: Frank Cichocki from the Study approvals NODCg-PrkdcscidIL2rgtm Wjl/SzJ (NSG) mice (Jackson Laboratories) were housed in the institution`s Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited animal care facility at Fate Therapeutics Torry Pines campus. All experiments were reviewed and approved by Fate Therapeutics Animal Care Committee (IACUC) under the protocol, O`Rouke. Patient MM cells were obtained from bone marrow biopsies performed at the Clinics and Surgery Center on the East Bank campus of the University of Minnesota with approval from the institutional review board (IRB). have published the article . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.